Journal article

Parecoxib as an adjunct therapy for the treatment of refractory non-surgical cancer pain

Arti Thakerar, Seamus Dines-Muntaner, Tijana Trifunovich, Marliese Alexander, Sonia Fullerton

Journal of Oncology Pharmacy Practice | SAGE PUBLICATIONS LTD | Published : 2020


BACKGROUND: Evidence for the use of short-term daily parenteral parecoxib for refractory or uncontrolled non-surgical cancer pain is limited. This study aimed to characterise the real-world off-label use and report on clinical experiences in an Australian cancer cohort. METHODS: Eligible patients received at least one dose of parecoxib of an intended three-day course between October 2015 and December 2018. Data were collected to characterise the parecoxib treatment cohort (cancer diagnosis, metastases, sites and types of pain and prior analgesia). Parecoxib-related adverse events, pain scores (worst and median), and concurrent opioid use were assessed at 24 h pre (T0) and 24 (T1), 48 (T2), 7..

View full abstract